Axsome Therapeutics, Inc.·4

Feb 25, 7:00 PM ET

Coleman Mark 4

4 · Axsome Therapeutics, Inc. · Filed Feb 25, 2026

Insider Transaction Report

Form 4
Period: 2026-02-23
Coleman Mark
Director
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-23$4.95/sh+6,250$30,93872,140 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1]
    2026-02-236,2507,721 total
    Exercise: $4.95From: 2018-03-15Exp: 2027-03-15Common Stock (6,250 underlying)
Holdings
  • Common Stock

    [F2]
    (indirect: See Footnote)
    403,856
Footnotes (2)
  • [F1]Represents the exercise of stock options, prior to the 10-year expiration date, for cash and hold of underlying shares.
  • [F2]Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.
Signature
/s/ Nick Pizzie, Attorney-in-Fact|2026-02-25

Documents

1 file
  • 4
    ownership.xmlPrimary

    4